How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?
Video navigation menu
- Undertreatment of CV risk factors is seen globally 0:09
- Ongoing CV outcomes trials of PCSK9 inhibitors as secondary prevention 1:21
- CV risk reduction in diabetes 3:07
- Long-term double antiplatelet therapy as secondary CV prevention 3:59
- Integrating PCSK9 inhibiting therapy into primary and secondary prevention 7:57
- How to combine anti-PCSK9 treatment with other preventive strategies? 8:53
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.